A systematic review and meta-analysis suggests that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may be associated with protective effects for patients with COVID-19. The analysis included 52 studies that evaluated clinical outcomes among 101 949 total patients, of whom 26.0% were receiving ACEIs or ARBs. When adjusted for covariates, significant reductions in the risk of death (adjusted odds ratio [aOR], 0.57) and severe adverse events (AEs, aOR, 0.68) were found. Unadjusted and adjusted analyses of a subgroup of patients with high blood pressure indicated decreases in the risk of death (unadjusted OR, 0.66; aOR, 0.51) and severe AEs (unadjusted OR, 0.70; aOR, 0.55). The findings are consistent with previous meta-analysis in patients with high blood pressure, extend to patients with multiple mixed comorbidities, and support the recommendations of medical societies to continue receiving ACEIs and ARBs for patients with COVID-19. Source: https://jamanetwork.com/
Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable…
The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of…
A single combined measure of high-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a)…
A French multicenter, open label, randomized, noninferiority trial suggested that interruption of long-term beta-blocker treatment…
A US prospective cohort study demonstrated that replacement of animal fat with an equivalent amount…
An ongoing UK national prospective program shows remission of type 2 diabetes (T2D) outside of…
This website uses cookies.